Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

D. F. Moore, R. Pazdur*, J. L. Abbruzzese, J. A. Ajani, D. W. Dubovsky, J. L. Wade, R. J. Belt, C. Mangold, B. Bready, R. J. Winn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background: The methotrexate analogue 10-ethyl-10-deazaaminopterin (10-EdAM, or edatrexate) has shown antitumor activity in preclinical testing and clinical studies of patients with breast, lung and head and neck carcinomas. A phase II study was conducted in patients with advanced pancreatic adenocarcinoma. Patients and methods: Forty patients were enrolled on the clinical trial. Edatrexate was administered intravenously at a dose of 80 mg/m2 weekly for 5 weeks. The treatment course was repeated every 6 weeks. Results: Two partial responses were observed. Both of these patients had partial responses which lasted 2 and 3.5 months. The median survival for all patients was 3.5 months. Serious (grade 3 or 4) toxic effects were primarily mucosal, hematologic, and dermatologic. Two patients experienced severe pulmonary toxic reactions. Conclusion: At the dose and schedule used, edatrexate was poorly tolerated and did not demonstrate significant antitumor activity.

Original languageEnglish (US)
Pages (from-to)286-287
Number of pages2
JournalAnnals of Oncology
Issue number3
StatePublished - Mar 1994


  • 10-EdAM
  • Antimetabolite
  • Edatrexate
  • Folate antagonist
  • Methotrexate
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this